Nectin Therapeutics

Nectin Therapeutics is a dynamic biotechnology company dedicated to unlocking the full potential of the immune system through innovative immunotherapy solutions. Focusing on next-generation immunotherapy agents, Nectin Therapeutics is committed to overcoming resistance mechanisms that limit the effectiveness of current treatments, thereby improving outcomes for cancer patients. The company operates out of its primary address at Hi-Tech Campus, Givat Ram Campus, Jerusalem, IL.

Nectin Therapeutics is actively developing a diverse pipeline of targeted antibodies, leveraging the nectin pathways to counteract inhibitory signals emitted by tumors. This approach empowers immune cells to more effectively target and eliminate cancer cells. Furthermore, Nectin Therapeutics is pioneering the development of CAR-T and CAR-NK drivers, capitalizing on the unique expression patterns of nectin proteins to directly target tumor cells across a range of indications, including those traditionally challenging to treat.

Nectin Therapeutics is steadfast in its mission to provide novel therapeutic options for cancer patients. The company's Jerusalem location fosters a collaborative environment conducive to breakthrough research and development. We invite the management team at Nectin Therapeutics to enhance your company's presence by creating a customized and exclusive company showcase and product listing on our platform, connecting with potential partners and investors.